Atul C Pande

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi request reprint Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study
    Atul C Pande
    Pfizer Global Research and Development, New London, CT 06320, USA
    J Clin Psychopharmacol 24:141-9. 2004
  2. ncbi request reprint A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder
    Douglas E Feltner
    Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    J Clin Psychopharmacol 23:240-9. 2003
  3. ncbi request reprint Long-term efficacy of pregabalin in generalized anxiety disorder
    Douglas Feltner
    Pfizer Global Research and Development, Ann Arbor, Missouri, USA
    Int Clin Psychopharmacol 23:18-28. 2008
  4. ncbi request reprint Pregabalin in generalized anxiety disorder: a placebo-controlled trial
    Atul C Pande
    Pfizer Global Research and Development, Ann Arbor Laboratories, MI, USA
    Am J Psychiatry 160:533-40. 2003
  5. ncbi request reprint Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing
    Robert B Pohl
    University Psychiatric Center, Wayne State University, Detroit, MI 48207, USA
    J Clin Psychopharmacol 25:151-8. 2005
  6. ncbi request reprint Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam
    Karl Rickels
    Department of Psychiatry, University of Pennsylvania, Philadelphia 19104 3309, USA
    Arch Gen Psychiatry 62:1022-30. 2005
  7. ncbi request reprint Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine
    Stuart A Montgomery
    Imperial College School of Medicine, London, UK
    J Clin Psychiatry 67:771-82. 2006

Detail Information

Publications7

  1. ncbi request reprint Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study
    Atul C Pande
    Pfizer Global Research and Development, New London, CT 06320, USA
    J Clin Psychopharmacol 24:141-9. 2004
    ..Somnolence and dizziness were the most frequently occurring adverse events among patients receiving pregabalin 600 mg/d. In conclusion, pregabalin 600 mg/d was an effective and well-tolerated treatment of social anxiety disorder...
  2. ncbi request reprint A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder
    Douglas E Feltner
    Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    J Clin Psychopharmacol 23:240-9. 2003
    ..This study supports the hypothesis that pregabalin is effective and safe in short-term therapy for GAD. More studies are needed to determine the best dosing regimen to optimize efficacy and tolerability...
  3. ncbi request reprint Long-term efficacy of pregabalin in generalized anxiety disorder
    Douglas Feltner
    Pfizer Global Research and Development, Ann Arbor, Missouri, USA
    Int Clin Psychopharmacol 23:18-28. 2008
    ..2%), headache (10.1 vs. 11.2%), and somnolence (6.0 vs. 0%). No safety concerns were identified with long-term treatment. The study indicates that pregabalin is an effective treatment for the prevention of relapse in patients with GAD...
  4. ncbi request reprint Pregabalin in generalized anxiety disorder: a placebo-controlled trial
    Atul C Pande
    Pfizer Global Research and Development, Ann Arbor Laboratories, MI, USA
    Am J Psychiatry 160:533-40. 2003
    ..Current drug therapies for generalized anxiety disorder have limitations. In a controlled trial, the novel agent pregabalin was studied for the treatment of patients with generalized anxiety disorder...
  5. ncbi request reprint Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing
    Robert B Pohl
    University Psychiatric Center, Wayne State University, Detroit, MI 48207, USA
    J Clin Psychopharmacol 25:151-8. 2005
    ..This study demonstrates that pregabalin is an effective treatment of generalized anxiety disorder, with BID dosing showing similar efficacy and comparable tolerability with TID dosing...
  6. ncbi request reprint Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam
    Karl Rickels
    Department of Psychiatry, University of Pennsylvania, Philadelphia 19104 3309, USA
    Arch Gen Psychiatry 62:1022-30. 2005
    ..Pregabalin inhibits release of excess excitatory neurotransmitters, presumably by binding to the alpha2-delta subunit protein of widely distributed voltage-dependent calcium channels in the brain and spinal cord...
  7. ncbi request reprint Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine
    Stuart A Montgomery
    Imperial College School of Medicine, London, UK
    J Clin Psychiatry 67:771-82. 2006
    ..The current study compared the efficacy and safety of pregabalin and venlafaxine in patients diagnosed with moderate to severe GAD...